KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Cash & Equivalents (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Cash & Equivalents data on record, last reported at $2.9 billion in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 3.52% year-over-year to $2.9 billion; the TTM value through Dec 2025 reached $2.9 billion, down 3.52%, while the annual FY2025 figure was $2.9 billion, 3.52% down from the prior year.
  • Cash & Equivalents reached $2.9 billion in Q4 2025 per EW's latest filing, up from $2.7 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $3.7 billion in Q3 2024 and bottomed at $761.5 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $1.8 billion, with a median of $1.3 billion recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: decreased 27.08% in 2021, then soared 168.94% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $862.8 million in 2021, then dropped by 11.74% to $761.5 million in 2022, then soared by 48.69% to $1.1 billion in 2023, then surged by 168.94% to $3.0 billion in 2024, then decreased by 3.52% to $2.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $2.9 billion in Q4 2025, $2.7 billion in Q3 2025, and $3.3 billion in Q2 2025.